TTrialPathMatch Me to Trials
← Back to trials
RecruitingRefractory Differentiated Thyroid Gland Carcinoma

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

32 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth of tumor cells and blood vessels the tumor needs to survive. Dabrafenib is an enzyme inhibitor that binds to and inhibits the activity of a protein called B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. Trametinib is also an enzyme inhibitor. It binds to and inhibits the activity of proteins called MEK 1 and 2, which play a key role in activating pathways that regulate cell growth. This may inhibit the growth of tumor cells mediated by these pathways. The usual approach for patients with thyroid cancer is targeted therapy with dabrafenib and trametinib. This trial may help researchers decide which treatment option (cabozantinib alone or dabrafenib in combination with trametinib) is safer and/or more effective in treating patients with refractory BRAF V600E-mutated differentiated thyroid cancer.

Sponsor: ECOG-ACRIN Cancer Research Group

You may qualify if…

  • ✓ Patient must be ≥ 18 years of age
  • ✓ Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • ✓ Patient must have differentiated thyroid cancer (DTC) with BRAF V600E mutation as determined by local testing, including the following subtypes (Note: results of a previous biopsy will be accepted):
  • ✓ Papillary thyroid carcinoma including histological variants of papillary thyroid carcinoma (PTC) such as follicular variant, tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated.
  • ✓ Follicular thyroid carcinoma including histological variants of follicular thyroid carcinoma (FTC) such as Hürthle cell, clear cell, insular, and poorly differentiated
  • ✓ Patient must have been previously treated with or deemed ineligible for treatment with Iodine-131 for DTC, and must be receiving thyroxine suppression therapy
  • ✓ Patient must have had prior treatment with at least one of the following vascular endothelial growth factor receptors (VEGFR)-targeting tyrosine kinase inhibitor (TKI) agents for DTC: lenvatinib or sorafenib.
  • ✓ NOTE: Up to two prior VEGFR-targeting TKI agents are allowed including, but not limited to lenvatinib and sorafenib

Where it's recruiting

Alaska

Anchorage · Fairbanks

Arkansas

Fort Smith · Little Rock

California

Burbank · Irvine · Napa · Orange …

Colorado

Aurora · Highlands Ranch

Connecticut

Derby · Fairfield · Glastonbury · Greenwich …

Florida

Fort Lauderdale · Jacksonville

Georgia

Atlanta

Idaho

Boise · Caldwell · Coeur d'Alene · Emmett …

Illinois

Alton · Aurora · Barrington · Centralia …

Indiana

Crown Point

Iowa

Ankeny · Bettendorf · Carroll · Cedar Rapids …

Kansas

Garden City · Great Bend · Pittsburg

Source: ClinicalTrials.gov · NCT06475989 · last updated 2026-11-16

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Ca · TrialPath